A Study to Evaluate Safety, Side Effects, Muscle Activity and Speed of Gastric Emptying of GSK962040

NCT00562848 | Completed Phase 1

• 1 other identifier: MOT107043
• Study Type: interventional
• Target: 48
• Locations: 1 country
• Sites: 1

Brief Summary

Motilin is a peptide whose action is controlled by motilin receptors located in the gut. Action of Motilin at motilin receptors increases the gastric emptying rate (rate of emptying of food and fluid from the stomach). Compounds which stimulate motilin receptors therefore provide a potential approach to the treatment of a range of clinical conditions where delayed gastric emptying may contribute to symptoms, such as enteral feeding intolerance (post-operative or intensive care patients), gastroparesis, diabetic gastroparesis, and functional dyspepsia. This study is the First Time In Human study for the motilin receptor agonist, GSK962040.

Conditions

Gastroparesis

Keywords

gastric emptying; pharmacokinetic; tolerability; safety; GSK962040; gut motility; First Time in Human

Outcome Measures

Primary Outcomes (5)

• Adverse Events -

  for 5 days

• Gastrointestinal symptoms -

  for 6 hours

• Blood pressure, heart rate, electrocardiography -

  for 48 hours

• Clinical chemistry/haematology -

  for 5 days

• Plasma pharmacokinetic parameters -

  for 5 days

Secondary Outcomes (3)

• Measurement of gastric emptying for 4.5 hours post-dose

  4.5 hours post-dose

• Measurement of stomach muscle activity for 24 hours post-dose

  24 hours post-dose

• Measurement of plasma pharmacokinetic and other blood tests for 3.5 hours post-dose

  3.5 hours post-dose

Study Arms (3)

Subjects enrolled in single dose escalation cohort

EXPERIMENTAL

Subjects will receive escalated doses of GSK962040 with a starting dose of 1 milligrams along with placebo in fasted state.

Drug: GSK962040; Drug: Placebo

Subjects enrolled in gastric emptying cohort

EXPERIMENTAL

Subjects will receive escalated doses of GSK962040 with a starting dose of 1 milligrams along with placebo in fasted state.

Drug: GSK962040; Drug: Placebo

Subjects enrolled in gastro-enteral contractility cohort

EXPERIMENTAL

Eligible subjects will receive GSK962040 and placebo in the fasted state in crossover manner.

Drug: GSK962040; Drug: Placebo

Interventions

GSK962040 DRUG

GSK962040 will be supplied in the following tablet strengths: 1 milligram, 5m milligrams, 25 milligrams, 125 milligrams.

Subjects enrolled in gastric emptying cohort; Subjects enrolled in gastro-enteral contractility cohort; Subjects enrolled in single dose escalation cohort

Placebo DRUG

Subjects will receive placebo.

Subjects enrolled in gastric emptying cohort; Subjects enrolled in gastro-enteral contractility cohort; Subjects enrolled in single dose escalation cohort

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy male or female subjects aged between 18 and 55 years inclusive. Healthy subjects are defined as individuals who are free from clinically significant illness or disease as determined by their medical history (including family), physical examination, laboratory studies, and other tests.
• A female subject may be enrolled in the study regardless of whether she is currently of non-childbearing potential or of childbearing potential, as long as the following conditions are observed:
• \- Females of non-childbearing potential: These are defined as females, regardless of their age, with functioning ovaries and who have a current documented tubal ligation \[Hatcher, 2004\] or hysterectomy, or females who are post-menopausal.
• \- Females of childbearing potential: These are defined as females, regardless of their age, with functioning ovaries and no documented impairment of oviductal or uterine function that would cause sterility. This category includes females with oligomenorrhea and females who are perimenopausal.
• To be eligible for the study, the female of childbearing potential
• must have a negative pregnancy test at screening before enrolment into the study; and
• must agree to use one of the highly effective methods for avoiding pregnancy in the protocol, from the Screening Visit throughout the duration of the study up to and including the follow-up clinic visit, which is anticipated to take place 7-10 days after the last dose of study medication (however the timing of the follow-up visit may be adjusted by File Note if it is indicated from the interim PK analyses). At this stage of development, there is no information on the potential pharmacokinetic interaction between GSK962040 and hormonal birth control methods, so the hormonal methods will not be acceptable.
• A 12-lead ECG at pre-study screening, which in the opinion of the Principal Investigator or physician designee has no abnormalities that will compromise safety in this study. QT/QTc criteria are defined in the protocol.
• A 24h Holter ECG at pre-study screening which in the opinion of the Principal Investigator or physician designee has no abnormalities that will compromise safety in this study.
• Normal physical examination (physical exam demonstrates no evidence of clinically active disease or physical or mental impairment).
• No abnormality on relevant clinical chemistry or haematology examination at the pre-study medical examination.
• Body weight ≥50 kg and BMI within the range 18.5-29.9 kg/m2 inclusive where BMI = Weight in kg (height in meters)2
• The volunteer is able to understand and comply with protocol requirements, instructions and protocol-stated restrictions.
• Signed and dated written informed consent prior to the performance of any study related procedure.
• Subjects will have negative Helicobacter pylori status or have received eradication within the last calendar year.

You may not qualify if:

• Use of any hormonal method of contraception or any form of HRT (female subjects only).
• History or presence of any clinically significant metabolic, gastrointestinal or endocrinological condition.
• History or presence of clinically significant gastro-intestinal, hepatic or renal disease or other condition known to interfere with the absorption, distribution, metabolism or excretion of drugs.
• History of major gastrointestinal surgical procedure within the last 10 years.
• History of cholecystectomy or biliary tract disease.
• History of immediate or delayed hypersensitivity reaction or idiosyncrasy to any drug, or other allergy that, in the opinion of the Principal Investigator or physician designee, contraindicates the subject's participation in the study. Additionally subjects with a known latex allergy should not be enrolled in C3.
• History or presence of corrected thyroid dysfunction (NOTE: subjects with hypothyroidism on a stable dose of thyroid replacement therapy are not eligible).
• Abnormal TSH or free T4 at screening/baseline.
• Unwillingness to commit to avoid excessive exposure to sunlight (or exposure whilst on a tanning bed) which would cause a sunburn reaction from Day -1 up to and including the follow-up visit.
• A positive pre-study HIV, Hepatitis B surface antigen or positive Hepatitis C antibody result at screening.
• History or presence of abuse of alcohol defined as an average weekly intake of greater than 21 units or an average daily intake of greater than 3 units.
• History or presence of recreational drug abuse or dependence.
• The subject has a positive pre-dose urine drug or alcohol breath test. A minimum list of drugs that will be screened for include Amphetamines, Barbiturates, Cocaine, Opiates, Cannabinoids and Benzodiazepines.
• If the subject is a tobacco smoker: An unwillingness to commit to stable and moderate use (as determined by the Investigator) of tobacco or nicotine-containing products, including nicotine patches/gum, during the course of the study.
• Consumption of grapefruit juice or grapefruit within 7 days prior to the first dose of study medication until the follow-up visit.

Sponsors & Collaborators

• GlaxoSmithKline: lead

Study Sites (1)

GSK Investigational Site

Leuven, 3000, Belgium

Location

Related Publications (1)

• Deloose E, Depoortere I, de Hoon J, Van Hecken A, Dewit OE, Vasist Johnson LS, Barton ME, Dukes GE, Tack J. Manometric evaluation of the motilin receptor agonist camicinal (GSK962040) in humans. Neurogastroenterol Motil. 2018 Jan;30(1). doi: 10.1111/nmo.13173. Epub 2017 Aug 6.

  PMID: 28782145 DERIVED

Related Links

• Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
• Results for study MOT107043 can be found on the GSK Clinical Study Register.

MeSH Terms

Conditions

Gastroparesis

Interventions

N-(3-fluorophenyl)-1-((4-(((3S)-3-methyl-1-piperazinyl)methyl)phenyl)acetyl)-4-piperidinamine

Condition Hierarchy (Ancestors)

Stomach Diseases; Gastrointestinal Diseases; Digestive System Diseases; Paralysis; Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Officials

• GSK Clinical Trials

  GlaxoSmithKline

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 21, 2007
• First Posted: November 22, 2007
• Study Start: September 10, 2007
• Primary Completion: June 27, 2008
• Study Completion: June 27, 2008
• Last Updated: August 8, 2017

Record last verified: 2017-08

Data Sharing

• IPD Sharing: Will share

Locations

BE (1)